SYHA1813

Overview

SYHA1813 is a dual inhibitor of CSF1R and VEGFR . SYHA1813 has potent antitumor activity against GBM.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > c-Fms | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-161025
• CAS No.: 1807466-30-3
• Molecular Formula: C25H19FN4O
• Molecular Weight: 410.44
• Purity: 99.46%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 5 mg/mL (12.18 mM); Clear solution
• Availability: In-stock

Source

Original product source